AlphAIalphai — Financial news for AI agents
Insider MonkeyMAR 314 min read$CHRS

Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why

Coherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.

Original reporting
Insider Monkey · Muhammad Ali Khalid
Published Mar 31, 2026, 7:23 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 8:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why — source image
Source · Insider Monkey
Decision brief

The 30-second read

$CHRSBullishMed
01

Why it matters

Positive earnings and strategic shifts suggest potential for stock appreciation, but inherent risks in biotech and penny stocks remain.

02

Market read

The news is highly relevant for investors interested in biotech growth stocks, especially those focusing on oncology.

03

What to watch

Potential regulatory hurdles, patent challenges, or market saturation could adversely affect future performance.

Timing: Immediate to short-term (next 1-3 months)

Background

Coherus Biosciences has transitioned from a generic biosimilar company to a focus on oncology, with recent financial improvements and pipeline developments.

Company-level read

Ticker impact

$CHRSBullishHigh confidence
Context

High relevance due to recent earnings report and positive sentiment.

Expected impact

Moderate to significant upward movement in the short to medium term, contingent on continued operational progress and market conditions.

Evidence & confidence

The earnings report indicates operational improvements and strategic shifts that are typically favorable for stock appreciation. The positive sentiment score and analyst expectations support this outlook.

Market effects

Sector

Potential positive impact on biotech and oncology sectors due to company’s focus shift and clinical pipeline advancements.

Regional

Primarily US-based market influence, with possible ripple effects in global biotech indices.

Global

Limited; company-specific news with localized impact.

Counterpoint

What could challenge this read

Some analysts may view the rapid growth and penny stock status as speculative and risky, warranting caution.

Key entities

  • Company
    Coherus Biosciences

    A biotechnology company focusing on oncology and biosimilars.

  • Product
    LOQTORZI

    A drug with increased sales contributing to revenue growth.

  • Financial Report
    Q4 2025 Earnings Report

    Quarterly financial results indicating operational progress.

Read at source← All news

Related articles

AUG 13
$CHRSMedAI 8/10

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.

fool.com6 min
AUG 7
$CHRSMed

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.

yahoo.com6 min
AUG 5
$CHRSMed

Coherus Oncology, Inc. (CHRS): Results of Operations and Financial Condition

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 chrs-20260805xex99d1.htm EX-99.1 Exhibit 99.1 ​ Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update ​ – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – ​ – Clinical data continue to mature across programs with

SEC EDGAR 8-K6 min
AUG 18
$RKLBMedAI 8/10

Rocket Lab Now Prime and Bus Supplier in GEO: Viasat Selects Lightning-GEO for Anti-Jam Satellite

Rocket Lab was selected by Viasat to supply the satellite bus for Viasat’s U.S. Space Force anti-jam Protected Tactical SATCOM-Global (PTS-G) Swarm 1 spacecraft, using Rocket Lab’s Lightning-GEO platform. Viasat will integrate, operate, and lead the prime role; Rocket Lab builds the bus. The Swarm 1 delivery order totals about $437.7M across contractors; terms were not disclosed.

techtimes.com7 min
AUG 17
$LHXMed

L3Harris ousts CEO Kubasik over conduct violation

L3Harris Technologies said CEO Christopher Kubasik stepped down after a board investigation found misconduct and the company entered a separation agreement. The company did not disclose details, saying the conduct was unrelated to financial reporting or operations. Sam Mehta was named successor. Reuters reported no severance, but he can keep vested options. LHX shares fell.

foxbusiness.com3 min